Survival of patients with deficient mismatch repair metastatic colorectal cancer in the pre-immunotherapy era.
G Emerens WensinkMarloes A G ElferinkAnne M MayLinda MolPatricia A H HamersSandra D BakkerGeert-Jan CreemersJan Willem B de GrootGerty J de KlerkBrigitte C M HaberkornAnnebeth W HaringhuizenRonald HoekstraJ Cornelis B HuntingEmile D KerverDanielle Mathijssen-van SteinMarco B PoléeJohannes F M PruijtPatricia Quarles van Ufford-MannesseSandra RademaRonald C RietbroekLieke H J SimkensBea C TanisDaan Ten Bokkel HuininkManuel L R Tjin-A-TonCathrien S Tromp-van DrielMonique M TroostAgnes J van de WouwFranchette W P J van den BerkmortelAnke J M van der PasAnkie M T van der VeldenMarjan A van DijkJoyce M van Dodewaard-de JongEdith B van DrutenTheo van VoorthuizenGerrit Jan VeldhuisHenk M W VerheulHanneke J H M J VestjensJeroen VincentOnno W KranenburgCornelis J A PuntGeraldine R VinkJeanine M L RoodhartMiriam KoopmanPublished in: British journal of cancer (2020)
Available data from immunotherapy trials lack a control arm with standard systemic treatment. Given the poor outcome compared to the immunotherapy results, our data strongly suggest a survival benefit of immunotherapy in dMMR mCRC patients.